Original Target Discovery Based on Life Processes and Innovative Drug Discovery Based on Biological Entity Engineering
Targetome, an international academic journal focusing on drug target research and translation, is committed to building a cutting-edge communication platform for the intersection of life sciences and pharmacy, and promoting the whole-chain innovation from target discovery, mechanism analysis to drug research and development. The dynamic regulatory mechanism of life processes is the core source of target discovery, while biological entity engineering technology provides a revolutionary tool for innovative drug research and development. To systematically present the latest research achievements in this field and promote interdisciplinary integration, we plan to publish a special issue themed “Original target discovery based on life processes and innovative drug discovery based on biological entity engineering”. We sincerely invite scholars worldwide to contribute high-quality manuscripts.
Scope of Submission
This special issue focuses on two core directions, and welcomes original research achievements, technical breakthroughs and translational application results related to the following contents:
1. Original target discovery based on life processes
Identification and verification of key regulatory targets in life processes such as cell proliferation, signal transduction, metabolic homeostasis and immune response;
Exploration of pathogenic targets in the occurrence and development of major diseases (such as inflammatory diseases, metabolic diseases, tumors, etc.) based on abnormal life processes;
Elucidation of the molecular mechanism of target regulation and its correlation with disease phenotypes;
Development and application of new technologies for target discovery based on life process analysis (such as single-cell sequencing, spatial transcriptomics, live cell imaging, etc.)
2. Innovative drug discovery based on biological entity engineering
Application of gene editing technology (CRISPRCas9, base editing, etc.) in the development of targeted drugs and cell therapy products;
Research on synthetic biology-driven microbial cell factories for the production of natural drug derivatives and innovative biological agents;
Development of engineered cells (CAR-T, CAR-NK, etc.) based on biological transformation and their translational research in disease treatment;
Innovation of drug delivery systems based on biological transformation (such as targeted nano-drugs, bacterial carriers, etc.);
Preclinical and clinical research of innovative drugs derived from biological transformation.
Guest Editors
Prof. Qinghua Hu, Faculty of Life Sciences and Technology, China Pharmaceutical University, China
Prof. Ligong Chen, School of Pharmaceutical Sciences, Tsinghua University, China
Prof. Volker M. Lauschke, Department of Physiology and Pharmacology, Karolinska Institute, Sweden
Deadline
The deadline for manuscript submissions is June 30, 2026, but we can accommodate extensions on a case-by-case basis. All papers will be published as open-access articles upon acceptance.
Submission Instructions
Please submit the full manuscript to Targetome via our Online Submission System. Additionally, please choose a topic of this special issue when submitting and mention it in your cover letter. For further inquiries, please contact Guest Editors:
Prof. Qinghua Hu (huqh@cpu.edu.cn)
Prof. Ligong Chen (lgchen@tju.edu.cn)
Prof. Volker M. Lauschke (volker.lauschke@ki.se)
-
{{article.year}}, {{article.volume}}({{article.issue}}): {{article.fpage | processPage:article.lpage:6}}. doi: {{article.doi}}{{article.year}}, {{article.volume}}({{article.issue}}): {{article.elocationId}} {{article.doi}}, doi: {{article.doi}}{{article.articleStateNameEn}}, doi: {{article.doi}}Abstract({{article.visitArticleCount}}) Abstract({{article.visitArticleCount}}) HTML HTML PDF({{article.pdfDownloadCount}}){{article.publishDate | date:'dd MMM yyyy' : 'UTC'}}Open Access
